Compare
Bristol Myers Squibb vs Johnson & Johnson (BMY vs JNJ)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Bristol Myers Squibb (BMY) returned +33.7% and Johnson & Johnson (JNJ) +48.5%; so far this year the figures are +15.2% and +33.5%.
Johnson & Johnson is the larger company by market value, about 5.2 times the size of Bristol Myers Squibb.
On trailing earnings, BMY trades at 13.8 times and JNJ at 41.9 times.
Revenue grew +4.2% at BMY and +7.8% at JNJ over the last year.
BMY yields 3.04%. JNJ yields 1.91%.
Data as of the latest close. Not investment advice.
Relative performance
| BMY | JNJ | |
|---|---|---|
| Price | $62.14 | $276.22 |
| 1-day | -1.57% | +1.43% |
| YTD | +15.20% | +33.47% |
| 1 year | +33.72% | +48.51% |
| 3 years | +21.18% | +85.77% |
| Market cap | $127.0B | $665.0B |
| P/E | 13.8 | 41.9 |
| P/S | 2.54 | 6.69 |
| P/B | 5.43 | 8.16 |
| Revenue growth | +4.20% | +7.80% |
| EPS growth | +52.40% | -36.40% |
| Gross margin % | 69.2 | 67.6 |
| Net margin % | 18.5 | 16.2 |
| ROE % | 39.5 | 19.7 |
| Debt / equity | 1.83 | 0.55 |
| FCF yield % | 7.3 | 3.1 |
| Dividend yield % | 3.04 | 1.91 |
| Beta | 0.25 | -0.09 |
| RSI (14) | 51.3 | 59.4 |
| Technical rating |